SV101 · SV-Delivery™
SV101 Delivery™ Mouse T cell targeted LNP
Species
Mouse
Primary target
T cell (mouse · pan-T)
Applications
in vitro / in vivo
Cargo compatibility
mRNA, saRNA, DNA
Particle size
80-100 nm
Freeze-thaw cycles tested
3
Published efficacy
Each result is shown with its evidence grade and source. Grade D entries are not displayed in production.
| Assay | Result | Grade | Source |
|---|---|---|---|
| Mouse CD4 T cells in vitro (GFP) | 94.1% GFP+ | A | SunVax conference 2026-05-03 slide 3 |
| Mouse CD8 T cells in vitro (GFP) | 79.8% GFP+ | A | SunVax conference 2026-05-03 slide 3 |
| Mouse CD19 B cells (specificity check) | 4.34% GFP+ (低选择性 · 不靶 B) | A | SunVax conference 2026-05-03 slide 3 |
| Balb/c in vivo CD4 T (2μg / 10μg) | 52.3% / 52.2% | A | SunVax conference 2026-05-03 slide 3 |
| Balb/c in vivo CD8 T (2μg / 10μg) | 49.7% / 56.5% | A | SunVax conference 2026-05-03 slide 3 |
Recommended in vitro dose
2-10 μg mRNA / 10⁶ cells
Recommended in vivo dose
2-10 μg / mouse IV
In vitro readout window
24-72h post-transfection · in vitro
In vivo readout window
Day 1 peak · day 8 ~10⁷ · day 15 ~10⁷ tail
Recommended controls
- PBS only (negative)
- Empty LNP (no cargo)
- Scrambled cargo (sequence specificity)
Known limitations
Honest disclosure: these are gaps in current SunVax data, not intended performance claims.
- PDX 数据不可外推到 human in vivo
- Repeat dosing 数据仍 limited
- Mouse-specific lipid · 不可直接用 human
Sources used on this page
- SunVax conference presentation 2026-05-03 · slide 2 (kits portfolio) and slide 3 (efficacy / stability data).
- SunVax product catalog at sunvaxmrna.com (last verified 2026-05-16).
- Per-result citations are shown in the "Published efficacy" table above with their evidence grade.
To request a correction or to ask for additional documentation on this kit, email yingzhongli@sunvaxmrna.com.